Presenting author
Christoph U Correll
3 presentations
W83. Using artificial intelligence/machine learning and real-world data to identify patients with schizophrenia for whom an aripiprazole monohydrate LAI is likely to be a favorable treatment option
T94. LB-102 for acute schizophrenia in adults: Results from the phase 2 NOVA1 clinical trial, focused on PANSS total score responder and CGI-S remitter rates
PS01-1103. Efficacy of adjunctive lumateperone 42 mg treatment across a broad range of depression symptoms in patients with major depressive disorder